Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple- dose, in vitro pharmacodynamic model

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 3, 1999, Pages 592-597

  Zelenitsky, S A ^a   Booker, B ^a   Laing, N ^b   Karlowsky, J A ^a,b   Hoban, D J ^a,b   Zhanel, G G ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; GLYCOPEPTIDE; ORITAVANCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; HOSPITAL INFECTION; MINIMUM INHIBITORY CONCENTRATION; MODEL; NONHUMAN; PRIORITY JOURNAL;

EID: 0033020091     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.3.592     Document Type: Article

References (21)

1. Blaser, J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl. A):125-130.
2. Blaser, J. 1991. Interactions of antimicrobial combinations in vitro: the relativity of synergism. Scand. J. Infect. Dis. 74(Suppl.):71-79.
3. Chien, J., S. Allerheligen, D. Phillips, B. Cerimele, and H. R. Thomasson. 1998. Safety and pharmacokinetics of single intravenous doses of LY333328 diphosphate (glycopeptide) in healthy men, abstr. A55, p. 18. In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
4. Curbelo, D. E., B. S. Koll, I. Wilets, and B. Raucher. 1997. Treatment and outcome of 100 patients with vancomycin resistant enterococcal (VRE) bacteremia, abstr. J7, p. 289. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. Edmond, M. B., J. F. Ober, D. L. Weinbaum, et al. 1995. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin. Infect. Dis. 20:1126-1133.
6. Garrison, M. W., K. Vance-Bryan, T. A. Larson, J. P. Toscano, and J. C. Rotschafer. 1990. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 34:1925-1931.
7. Gaynes, R., and J. Edwards. 1996. National Nosocomial Infection Surveillance System. Nosocomial vancomycin resistant enterococci (VRE) in the United States. 1989-1995: the first 1000 isolates, abstract 13. Infect. Control Hosp. Epidemiol. 17(5 pt. 2) (Suppl.):18.
8. Iwen, P. C., D. M. Kelly, J. Linder, S. H. Hindrichs, E. A. Dominguez, M. E. Rupp, and K. D. Patil. 1997. Change in prevalence and antibiotic resistance of Enterococcus species isolated from blood cultures over an 8-year period. Antimicrob. Agents Chemother. 41:494-495. (Letter.)
9. Jones, R. N., M. S. Barrett, and M. E. Erwin. 1996. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Antimicrob. Agents Chemother. 41:488-493.
10. Landman, D., and J. M. Quale. 1997. Management of infections due to resistant enterococci: a review of therapeutic options. J. Antimicrob. Chemother. 40:161-170.
11. Leclerque, R., and P. Courvalin. 1997. Resistance to glycopeptides in enterococci. Clin. Infect. Dis. 24:545-556.
12. Mercier, R.-C., H. H. Houlihan, and M. J. Rybak. 1997. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob. Agents Chemother. 41:1307-1312.
13. National Committee for Clinical Laboratory Standards. 1995. Approved standard. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. Nicas, T. L., D. L. Mullen, J. E. Flokowitsch, D. A. Preston, N. J. Snyder, R. E. Stratford, and R. D. G. Cooper. 1995. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria. Antimicrob. Agents Chemother. 39:2585-2587.
15. Nicas, T. L., D. L. Mullen, J. E. Flokowitsch, D. A. Preston, N. J. Snyder, S. C. Zweifel, S. C. Wilkie, M. J. Rodreguez, R. C. Thompson, and R. D. G. Cooper. 1996. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 40:2194-2199.
16. Schwalbe, R. S., A. A. McIntosh, S. Qaiyumi, J. A. Johnson, R. J. Johnson, K. M. Furness, W. J. Holloway, and L. Steele-Moore. 1996. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob. Agents Chemother. 40:2416-2419.
17. Stratton, C. W. 1993. Bactericidal testing. Infect. Dis. Clin. N. Am. 7:445-459.
18. Vergis, E. N., J. W. Chow, M. K. Haydn, D. R. Snydman, M. J. Zervos, P. K. Linden, M. M. Wagener, and R. R. Muder. 1997. Vancomycin resistance predicts mortality in enterococcal bacteremia: a prospective, multicenter study of 375 patients, abstr. J6, p. 289. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C.
19. Woodford, N., A. P. Johnson, D. Morrison, and D. C. E. Speller. 1995. Current perspectives on glycopeptide resistance. Clin. Microbiol. Rev. 8:585-615.
20. Zelenitsky, S. A., J. A. Karlowsky, G. G. Zhanel, D. J. Hoban, and T. Nicas. 1997. Synergistic activity of an investigational glycopeptide, LY333328, and gentamicin against vancomycin-sensitive and vancomycin-resistant Enterococcus faecium, abstr. 4296, p. 150. In Program and abstracts of the 20th International Congress of Chemotherapy.
21. Zelenitsky, S. A., J. A. Karlowsky, G. G. Zhanel, D. J. Hoban, and T. Nicas. 1997. Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains. Antimicrob. Agents Chemother. 41:1407-1408. (Letter.)